FindTrial
Sign In

Safety and effectiveness of remimazolam combined with Butorphanol in hysteroscopy

Safety and effectiveness of remimazolam combined with Butorphanol in hysteroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049786
Enrollment
Unknown
Registered
2021-08-09
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopic surgery

Interventions

Group C:remimazolam+Butorphanol
Group A:Propofol
Group B:Propofol+Butorphanol

Sponsors

Jingmen First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Choose 300 patients who come to our hospital for hysteroscopic surgery from May 2020 to May 2021, aged 20-60 years, ASA classification I-II grade, BMI 18-22kg/m2, all patients need to sign an informed consent form.

Exclusion criteria

Exclusion criteria: Drug contraindications, contraindications to hysteroscopic surgery, heart, liver, and kidney dysfunction; people with a history of asthma; alcohol abusers; people with mental illness or diabetes.

Design outcomes

Primary

MeasureTime frame
Mean arterial pressure;Respiratory rate;Adverse reactions;VAS pain score;Wake up time;—

Countries

China

Contacts

Public ContactYang Changming

Jingmen First People's Hospital

hbjmyangcm@126.com+86 13908691882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026